文献速递咽喉与嗓音

新型可注射生物分子支持喉返神经长期修复及部分周围神经修复

Novel Injectable Supports Long-Term Recurrent Laryngeal Nerve and Partial Peripheral Nerve Repair.
PubMed 文献 · Laryngoscope · 2026-09-13

本研究在成年C57BL/6小鼠中测试Agrin、NRG1和ACh混合注射对喉返神经及坐骨神经损伤的修复效果。结果显示该生物分子治疗改善喉返神经损伤后的声带运动和肌电对称性,促进神经肌肉接头形成并保留肌纤维完整性;在坐骨神经模型中仅显示结构性再生而无持续功能恢复。

要点

  • Agrin/NRG1/ACh注射可改善喉返神经损伤后声带运动及肌电对称性。
  • 该治疗促进喉返神经支配的甲杓肌神经肌肉接头形成并保留肌纤维完整性。
  • 坐骨神经损伤模型中该治疗仅显示结构再生,未产生有意义的功能恢复。

核心结论

  • 生物分子治疗支持喉返神经损伤后的功能与结构再生。
  • 在坐骨神经模型中仅显示结构性而非持续功能性恢复。
  • 更大周围神经的再生可能需要持续递送或重复给药。

研究设计与样本

  • 成年C57BL/6小鼠单侧喉返神经或坐骨神经切断模型。
  • 喉返神经和坐骨神经队列各含生理盐水组(N=5)、生物分子组(Agrin、NRG1、ACh)(N=5)和未损伤对照组(N=5)。
  • 喉返神经功能评估采用视频喉镜和肌电图,坐骨神经采用步态分析和肌电图。
  • 组织学结局包括免疫组化和甲杓肌或腓肠肌肌纤维直径。

主要发现

  • 喉返神经模型中生物分子治疗改善声带运动并恢复肌电对称性,符合功能性再支配。
  • 组织学显示神经肌肉接头形成增加且肌纤维完整性得以保留。
  • 坐骨神经模型中治疗未基于肌电图和步态缺陷产生有意义的功能恢复。
  • 坐骨神经模型显示神经大体连续性、神经丝染色增加和肌纤维结构保留,提示部分结构再生。

临床怎么用

  • 该生物分子注射策略可能为喉返神经损伤提供靶向再支配治疗方向。
  • 对较大周围神经损伤,需考虑持续递送或重复给药方案。

局限性

  • 研究为小鼠模型,样本量较小(每组N=5)。
  • 坐骨神经模型未观察到持续功能恢复。
  • 证据等级为N/A。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Unilateral vocal fold paralysis (VFP) from recurrent laryngeal nerve (RLN) injury currently has no injectable treatment options that promote targeted reinnervation. In a prior pilot study, Agrin, neuregulin-1 (NRG1), and acetylcholine (ACh) enhanced early (1-month) reinnervation after RLN injury. The aims of the current study were to (1) assess if these effects persist in a 3-month RLN injury model and (2) test whether Agrin/ACh/NRG1 promotes regeneration after sciatic nerve (SN) transection, with relevance to nerve repair beyond the larynx. METHODS: Adult C57BL/6 mice underwent unilateral RLN or SN transection with injections into the thyroarytenoid or gastrocnemius, respectively. Separate RLN and SN cohorts included saline (N = 5), biomolecule (Agrin, NRG1, ACh) (N = 5), and uninjured controls (N = 5). Functional recovery was evaluated using videolaryngoscopy and electromyography (EMG) for RLN injury, and gait analysis with EMG for the SN model. Histologic outcomes included immunohistochemistry and myofiber diameter of the thyroarytenoid or gastrocnemius muscles. RESULTS: Biomolecule treatment improved vocal fold movement and restored EMG symmetry in the RLN model, consistent with functional reinnervation. Histology demonstrated increased NMJ formation and preserved myofiber integrity. In the SN model, treatment did not produce meaningful functional recovery based on EMG and gait deficits. However, gross nerve continuity, increased neurofilament staining, and preserved myofiber architecture indicated partial structural regeneration. CONCLUSIONS: Biomolecule therapy supports functional and structural regeneration following RLN injury and demonstrates structural, but not sustained functional, recovery in the SN model. Further investigation into sustained delivery or repeat dosing may be necessary to support regeneration in larger peripheral nerves. LEVEL OF EVIDENCE: N/A.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Bhatt A, Boswell W, Kennedy E, et al. Novel Injectable Supports Long-Term Recurrent Laryngeal Nerve and Partial Peripheral Nerve Repair. Laryngoscope. 2026. PMID: 42732967. doi:10.1002/lary.70873

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。